|
|
|
| Relationship between Serum LncRNA-MSC-AS1 Level and Clinicopathological Features and Prognosis in Patients with Ovarian Cancer |
| LI Cui'e, HE Xiaoli, HE Jieli, et al |
| Jianli People's Hospital, Hubei Jianli 433300, China |
|
|
|
|
Abstract Objective: To explore the relationship between serum long-stranded non-coding RNA myoprotein antisense RNA 1 (LncRNA-MSC-AS1) level and clinicopathological features and prognosis in patients with ovarian cancer (OC). Methods: A total of 106 OC patients admitted to our hospital from November 2016 to November 2018 were taken as the OC group, and 106 normal healthy subjects were taken as the control group. The expression level of LncRNA-MSC-AS1 in serum was detected by quantitative real-time PCR (qRT-PCR); Kaplan-Meier survival curve was used to analyze the relationship between LncRNA-MSC-AS1 expression level and 3-year survival in OC patients; Cox regression analysis of risk factors affecting adverse prognosis of OC patients at 3 years after surgery. Results: The expression of LncRNA-MSC-AS1 in OC group (0.75±0.08) was lower than that in control group (1.01±0.11) (t=19.681, P<0.05); the expression level of LncRNA-MSC-AS1 in OC patients was correlated with TNM stage, lymph node metastasis, tumor diameter, and CA125 (P<0.05); Kaplan-Meier survival curve analysis showed that the 3-year survival rate of the high expression group of LncRNA-MSC-AS1 was 71.15% (37/52), which was significantly higher than that of the low expression group (37.04% (20/54). (Log rank χ2=12.404, P<0.001); COX regression analysis showed that TNM stage, tumor diameter, low expression of CA125 and LncRNA-MSC-AS1 were risk factors for poor prognosis of OC patients at 3 years after operation (P<0.05). Conclusion: LncRNA-MSC-AS1 is under-expressed in OC patients, which is related to the clinicopathological characteristics and prognosis of OC patients, and is expected to be a potential biomarker for OC prognosis assessment.
|
|
|
|
|
|
[1] 王媛媛,魏殿军,周琛.miR-129-5p靶向HMGB1对卵巢癌细胞增殖,侵袭和迁移的影响及分子机制[J].现代免疫学,2020,40(3):209-215.
[2] 郭丽璇,胡琼英,付新刚,等.RDW和CA125联合应用对卵巢癌早期诊断的价值评价[J].现代预防医学,2020,47(6):1079-1081.
[3] 李小琳,韩艳艳,杨雪,等.卵巢癌的分子靶向治疗进展[J].实用癌症杂志,2020,35(4):695-696.
[4] 宋洋,任芳.miR-590-5p介导lncRNA SNHG1信号影响卵巢癌细胞增殖的实验研究[J].现代肿瘤医学,2020,28(14):2365-2369.
[5] Zhang N,Hu X,He S,et al.LncRNA MSC-AS1 promotes osteogenic differentiation and alleviates osteoporosis through sponging microRNA-140-5p to upregulate BMP2-ScienceDirect[J].Biochemical and Biophysical Research Communications,2019,519(4):790-796.
[6] Zhao Y,Yuan D,Zhu D,et al.LncRNA-MSC-AS1 inhibits the ovarian cancer progression by targeting miR-425-5p[J].Journal of Ovarian Research,2021,14(1):109.
[7] 周琦,吴小华,刘继红,等.卵巢恶性肿瘤诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):490-500.
[8] 汤明,方春田,王燕,等.卵巢癌组织中circKIF4A和miR-942-5p的表达及其与患者临床病理特征及预后的关系[J].河北医学,2023,29(1):126-131..
[9] 李小丹,郭红燕,李圆.初级与次级预防性使用聚乙二醇化重组人粒细胞集落刺激因子在卵巢癌初始肿瘤细胞减灭术后化疗的价值[J].中国微创外科杂志,2022,22(3):197-201.
[10] 刘浪,王微娜,赵俞乔,等.异常表达的EGFR-AS1在恶性肿瘤中的作用与机制研究[J].肿瘤学杂志,2021,27(10):854-859.
[11] 冯玉杰.TNF-α诱导的长非编码RNA LOC105374902在宫颈癌细胞中的作用及调控机制研究[D].天津医科大学,2020.
[12] Sun Y,Wang P,Yang W,et al.The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis[J].Cancer Biology & Therapy,2019,20(6):729-739.
[13] Kou X,Zhu J,Xie X,et al.Expression of lncRNA MSC-AS1 in hepatocellular carcinoma cell lines and its effect on proliferation,apoptosis and migration[J].The Turkish Journal of Gastroenterology,2020,31(12):19485.
[14] Gu J X,Zhang X,Miao R C,et al.Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma[J].World Journal of Gastroenterology,2019,25(2):220-232.
[15] 刘雪芬,张国福,金俊,等.磁共振成像在上皮型卵巢癌分型中的鉴别价值及表观弥散系数值与CA-125和Ki-67表达及预后的关系[J].复旦学报:医学版,2020,47(4):567-573. |
|
|
|
2023, Vol. 29 
